# Clinical Evaluation of Ujiplus® Against Schistosoma Mansoni

> **NCT04679831** · PHASE2,PHASE3 · COMPLETED · sponsor: **Kenya Medical Research Institute** · enrollment: 400 (actual)

## Conditions studied

- Schistosoma Mansoni

## Interventions

- **DIETARY_SUPPLEMENT:** Ujiplus®
- **DRUG:** Praziquantel 400mg

## Key facts

- **NCT ID:** NCT04679831
- **Lead sponsor:** Kenya Medical Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-06
- **Primary completion:** 2022-03-30
- **Final completion:** 2022-03-30
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2022-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04679831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04679831, "Clinical Evaluation of Ujiplus® Against Schistosoma Mansoni". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04679831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*